NVP-BEZ235 – 25 mg

Brand:
Cayman
CAS:
915019-65-7
Storage:
-20
UN-No:
Non-Hazardous - /

Phosphatidylinositol 3-kinase (PI3K) signaling through Akt/PKB and the mammalian target of rapamycin (mTOR) controls gene expression related to cell proliferation, differentiation, and apoptosis. Increased activity of this pathway is important in many types of cancer. NVP-BEZ235 is a potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies.{18570,18573} It inhibits PI3K isoforms and mutants with low nanomolar IC50 values, leading to growth arrest in the G1 phase.{18570,18572} Through its effects on PI3K, NVP-BEZ235 inhibits VEGF-induced angiogenesis.{18571} By directly blocking cell growth and indirectly inhibiting angiogenesis, it has potential in both solid tumors and in metastatic melanoma therapy.{18574,18575}  

 

Available on backorder

SKU: 10565 - 25 mg Category:

Description

A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anti-cancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis


Formal name: 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-α,α-dimethyl-benzeneacetonitrile

Synonyms:  ​Dactolisib

Molecular weight: 469.5

CAS: 915019-65-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|mTOR||Product Type|Biochemicals|Kinase Inhibitors|PI3K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling